220 related articles for article (PubMed ID: 19362987)
1. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
[TBL] [Abstract][Full Text] [Related]
2. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
[TBL] [Abstract][Full Text] [Related]
3. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Branagan A; Hunter Z; Treon SP
Arch Ophthalmol; 2006 Nov; 124(11):1601-6. PubMed ID: 17102008
[TBL] [Abstract][Full Text] [Related]
4. Role of plasmapheresis in Waldenström's macroglobulinemia.
Stone MJ; Bogen SA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642
[TBL] [Abstract][Full Text] [Related]
5. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.
Stone MJ
Clin Lymphoma Myeloma; 2009 Mar; 9(1):97-9. PubMed ID: 19362986
[TBL] [Abstract][Full Text] [Related]
6. [Alleviation of ocular complications of the hyperviscosity syndrome in Waldenström's macroglobulinemia using plasma exchange].
Malecaze F; Mathis A; Gonzales C; Lloveras JJ; Goudable C; Arlet P; Bec P
J Fr Ophtalmol; 1986; 9(5):367-71. PubMed ID: 3100607
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
8. Hyperviscosity retinopathy. A scientific approach to therapy.
Grindle CF; Buskard NA; Newman DL
Trans Ophthalmol Soc U K (1962); 1976 Jul; 96(2):216-9. PubMed ID: 827830
[No Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
10. The use of emergency apheresis in the management of plasma cell disorders.
Kalayoglu-Besisik S
Transfus Apher Sci; 2018 Feb; 57(1):35-39. PubMed ID: 29477943
[TBL] [Abstract][Full Text] [Related]
11. Hyperviscosity syndrome in plasma cell dyscrasias.
Mehta J; Singhal S
Semin Thromb Hemost; 2003 Oct; 29(5):467-71. PubMed ID: 14631546
[TBL] [Abstract][Full Text] [Related]
12. Hyperviscosity syndrome in Waldenström's macroglobulinemia.
Krol TC; Wood WS
Am Fam Physician; 1981 Aug; 24(2):187-9. PubMed ID: 6789661
[No Abstract] [Full Text] [Related]
13. Hyperviscosity in plasma cell dyscrasias.
Kwaan HC
Clin Hemorheol Microcirc; 2013; 55(1):75-83. PubMed ID: 23455837
[TBL] [Abstract][Full Text] [Related]
14. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Pilon AF; Rhee PS; Messner LV
Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
16. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Gustine JN; Meid K; Dubeau T; Hunter ZR; Xu L; Yang G; Ghobrial IM; Treon SP; Castillo JJ
Br J Haematol; 2017 Jun; 177(5):717-725. PubMed ID: 28485115
[TBL] [Abstract][Full Text] [Related]
17. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
Srour M; Kassab I; Matta H; Elkak A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
19. Plasma exchange in the long-term management of Waldenström's macroglobulinemia.
Buskard NA; Galton DA; Goldman JM; Kohner EM; Grindle CF; Newman DL; Twinn KW; Lowenthal RM
Can Med Assoc J; 1977 Jul; 117(2):135-7. PubMed ID: 406031
[TBL] [Abstract][Full Text] [Related]
20. Waldenstrom's macroglobulinemia, a hyperviscosity manifestation of venous stasis retinopathy.
Feman SS; Stein RS
Int Ophthalmol; 1981 Aug; 4(1-2):107-12. PubMed ID: 6795138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
